Regulatory status and access

Approvals, the compounding story, and getting the real thing

The final teaching unit steps back to the system around the drug: how it was approved, where it is available, and the turbulent compounding saga driven by shortage and demand. These access issues shape who actually gets tirzepatide and in what form.

It closes on the practical distinction that matters most for safety: branded, tested product versus the compounded and gray-market versions that surged during the shortage.